Lv Haiying, Chen Tongtong, Pan Yaling, Wang Hanqi, Chen Liuping, Lu Yong
Department of Radiology, Ruijin Hospital/Lu Wan Branch, School of Medicine, Shanghai Jiaotong University, Shanghai, China.
Ann Transl Med. 2020 Jul;8(14):878. doi: 10.21037/atm-20-4955.
The 2019 coronavirus disease (COVID-19) has become a global pandemic. To date, although many studies have reported on the computed tomography (CT) manifestations of COVID-19, the vascular enlargement sign (VES) of COVID-19 has not been deeply examined, with the few available studies reporting an inconsistent prevalence. We thus performed a systematic review and meta-analysis based on the best available studies to estimate the prevalence and identify the underlying differential diagnostic value of VES.
We searched nine English and Chinese language databases up to April 23, 2020. Studies that evaluated CT features of COVID-19 patients and reported VES, with or without comparison with other pneumonia were included. The methodologic quality was assessed using Quality Assessment of Diagnostic Accuracy Studies-2 (QUADAS-2). Meta-analyses with random effects models were performed to calculate the aggregate prevalence and pooled odds ratios (ORs) of VES. We also conducted meta-regression and subgroup analyses to analyze heterogeneity.
VES findings from a total of 1969 patients were summarized and pooled across 22 studies. Our analysis demonstrated that the prevalence of VES among COVID-19 patients was 69.37% [95% confidence interval (CI): 57.40-79.20%]. Compared with non-COVID-19 patients, VES manifestation was more frequently observed in confirmed COVID-19 patients (OR =6.43, 95% CI: 3.39-12.22). Studies that explicitly defined distribution of VES in the lesion area demonstrated a significantly higher prevalence (P=0.03). Subgroup analyses also revealed a relatively higher VES rate in studies with a sample size larger than 50, but the difference was not statistically significant. No significant difference in VES rates was found between different countries (China/Italy), regions (Hubei/outside Hubei), average age groups (over/less than 50-year-old), or slice thicknesses of CT scan. Extensive heterogeneity was identified across most estimates (I>80%). Some of the variations (R=19.73%) could be explained by VES distribution, and sample size. No significant publication bias was seen (P=0.29).
VES on thoracic CT was found in almost two-thirds of COVID-19 patients, and was more prevalent compared with that of the non-COVID-19 patients, supporting a promising role for VES in identifying pneumonia caused by coronavirus.
2019冠状病毒病(COVID-19)已成为全球大流行疾病。迄今为止,尽管许多研究报道了COVID-19的计算机断层扫描(CT)表现,但COVID-19的血管增粗征(VES)尚未得到深入研究,现有少数研究报告的患病率不一致。因此,我们基于现有最佳研究进行了系统评价和荟萃分析,以估计VES的患病率并确定其潜在的鉴别诊断价值。
我们检索了截至2020年4月23日的9个中英文数据库。纳入评估COVID-19患者CT特征并报告VES的研究,无论是否与其他肺炎进行比较。使用诊断准确性研究质量评估-2(QUADAS-2)评估方法学质量。采用随机效应模型进行荟萃分析,计算VES的总体患病率和合并比值比(OR)。我们还进行了荟萃回归和亚组分析以分析异质性。
汇总并综合了22项研究中1969例患者的VES结果。我们的分析表明,COVID-19患者中VES的患病率为69.37%[95%置信区间(CI):57.40-79.20%]。与非COVID-19患者相比,确诊的COVID-19患者中更常观察到VES表现(OR = 6.43,95% CI:3.39-12.22)。明确界定VES在病变区域分布的研究显示患病率显著更高(P = 0.03)。亚组分析还显示,样本量大于50的研究中VES发生率相对较高,但差异无统计学意义。不同国家(中国/意大利)、地区(湖北/湖北以外)、平均年龄组(50岁以上/50岁以下)或CT扫描层厚之间VES发生率无显著差异。大多数估计值存在广泛的异质性(I>80%)。部分变异(R = 19.73%)可由VES分布和样本量解释。未发现显著的发表偏倚(P =